A 1 -A 2 9 8 Kong SLE patients compared to standard care. METHODS: A lifetime microsimulation model was adapted with epidemiological and cost data from Hong Kong. The model compares the use of belimumab against standard care and incorporates the BLISS-52 and BLISS-76 trial data for the short term outcomes within one year, while long-term outcomes were based on a natural history model developed using the Johns Hopkins Lupus registry. The natural history model describes the relationship between disease activity and other covariates on the risk of dying and developing organ damage. Data available from the SLE population in Hong Kong was used as input in the modified model. The analysis was performed from a Hong Kong health-care perspective. In the base case, cost and effectiveness were discounted to the year of analysis at 5% p.a. RESULTS: The base case analysis showed that compared to standard care, treatment with belimumab increased life expectancy by 0.80 (2.77 undiscounted) and QALY by 0.60 (1.68 undiscounted) years respectively.
PSY43 ECONOMIC ASSESSMENT OF THE PROPHYLAXIS VERSUS ON-DEMAND APPROACH FOR THE TREATMENT OF HEMOPHILIA A IN YOUNG PATIENTS IN MEXICO
Muciño-Ortega E 1 , Salinas-Escudero G 2 , Galindo-Suárez RM 1 1 Pfizer S. A. de C.V., Mexico City, Mexico, 2 Hospital Infantil de México Federico Gómez, Secretaría de Salud, Mexico City, Distrito Federal, Mexico OBJECTIVES: Hemophilia A is a disease with extreme disabling consequences. Prophylaxis helps to diminish them, but its cost should be assessed. The study was intended to estimate the economic and health consequences of prophylaxis vs on-demand supply of factor VIII (FVIII) in the management of patients with hemophilia A, from the perspective of Instituto Mexicano del Seguro Social (IMSS). METHODS: A three-state, two-week cycle Markov model simulated hemophilia in children from age 2 to 18 in two arms: prophylaxis with recombinant FVIII (25UI moroctocog alfa/kg every other day) and infusions of 40UI/kg of plasma derived FVIII for spontaneous bleeds. The number of bleeds per approach, utilities and infusions required to control spontaneous bleeds were extracted from international literature. Both weight per age and probability of death were extracted from Mexican sources. Effectiveness measures were QALYs and bleeds avoided. The model assumed that safety and effectiveness profiles of both types of FVIII are equivalents, with no differences in costs of administration or adverse event management. Only the costs of acquisition of FVIII and emergency room were considered (both extracted from IMSS sources). Both costs and consequences were discounted at 5%/year. The costs are expressed in 2012 US$. Univariate sensitivity analysis was performed. RESULTS: There were 69% fewer bleeds in the prophylaxis group than in the on-demand group (50.7 vs 162.9, respectively), whereas the cost of prophylaxis represented 5.6 times the cost of on-demand ($730,810 vs. $129,912, respectively), the ICER was $5,355.83/avoided bleed. Patients under prophylaxis gained 2.39 QALYs (9.88 vs. 7.50), with an ICER of $251,876/QALY. The model is very sensitive to probability of spontaneous bleeding and dose in prophylaxis. CONCLUSIONS: From IMSS´s perspective, prophylaxis with moroctocog alfa for the management of patients with hemophilia A would bring highly valuable health benefits to patients, but more resources would need to be invested.
PSY44

COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL THERAPIES FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN INSTITUTIONAL MARKET IN ECUADOR
Torres Toala FG 1 , Albuja Riofrio MF 2 , Mould Quevedo JF 3 , Estévez C 4 1 MAKROSE, QUITO, Ecuador, 2 PFIZER, QUITO, Ecuador, 3 Pfizer, Inc., New York, NY, USA, 4 Pfizer INC, Quito, Ecuador OBJECTIVES: Psoriasis is a chronic skin disease that strongly affects quality of life of its patients. In Ecuador, this disease affects 0.59% of the population and is estimated that 650 new patients are diagnosed every year with psoriasis according to the Ecuadorian National Foundation of Psoriasis. Biologic treatments had dramatically changed the therapeutics, outcomes and cost of management of these patients. The aim of this study is to assess the costeffectiveness of biologic alternatives available in Ecuador to treat moderate to severe psoriasis adult patients from a public payer's perspective. METHODS: A decision-tree model was developed to simulate the clinical course of patients (18yrs+) treated with etanercept (50mg per week), adalimumab (80 mg on week 0, thereafter 40 mg every 2 weeks) and infliximab (5 mg/kg at weeks 0, 2, 6 and thereafter every 8 weeks) as first-line therapies, as well as treatment associated costs (2-year timeframe with a 5% annual discount rate). Effectiveness measures were the percentage of patients reaching 75% improvement using the Psoriasis Area and Severity Index (PASI-75) and quality adjusted life years gained (QALY´s). Costs considered included: biologic acquisition costs, concomitant medication, medical follow-up and side effects management. Clinical response of alternatives was extracted from published literature. Unit costs were collected from official Ecuadorian databases (Ministry of Health, National Social Security). RESULTS: After two years, the percentage of patients reaching PASI-75 were 59.1%, 62.1% and 62.4% for adalimumab, etanercept and infliximab respectively (p=0.077, Friedman test). QALY´s associated to each alternative were: 1.50, 1.53 and 1.53, respectively. Expected mean costs per patient were: US$ 66,240 for adalimumab; US$ 39,585 for etanercept and US$ 49,055.6 for Infliximab. These results were supported through probabilistic sensitivity analyses. CONCLUSIONS: In Ecuador, the less expensive therapy to treat moderate to severe adult psoriasis patients would be etanercept.
PSY45
COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE TREATMENT OF NEUROPATHIC PAIN IN COLOMBIA
Ordoñez Molina JE 1 , Orozco Giraldo JJ 1 , Gutierrez-Ardila MV 2 1 CES University, Medellin, Colombia, 2 Pfizer S.A.S., Bogota, Colombia OBJECTIVES: Neuropathic pain is caused by various disorders affecting the central and peripheral nervous system. Its most common causes are secondary to herpes zoster infection and as a complication of diabetes mellitus. The aim of this analysis is to evaluate the cost-effectiveness of pregabalin versus duloxetine to estimate the pain reduction in diabetic neuropathy and postherpetic neuralgia from the social perspective in Colombia. METHODS: A Markov model was developed with 3 health-states: improvement (pain reduction >50% using visual analogue scale [VAS] against baseline), no improvement and treatment discontinuation (due to therapeutic failure). The time horizon is of 5 years (threemonth cycles) and discounts annually effectiveness and costs using a 3% rate. Comparators were pregabalin (150-300 mg/day) vs. duloxetine (60 mg/day). Population (>18 years) with neurophatic pain was estimated in 775,152 for Colombia. Effectiveness and utility data were taken from a literature and metaanalysis of controlled clinical trials. Costs were taken from official tariff manuals, pricing laws and from the local health insurance company SURA. Costs are presented in 2012 USD. Effectiveness measure was Quality Adjusted Life Years (QALYs). RESULTS: Over a 5-year period, pregabalin obtained 231,105 QALYs more than duloxetine (1,003,720 and 772,615 QALYs, respectively). Total expected savings with pregabalin was USD439.5M compared to duloxetine (total expected costs: USD664.8M and USD1,104.4M, respectively); costs for medical disabilities (sick leaves) were USD43.8 lower with pregabalin than duloxetine. Probabilistic sensitivity analyses showed the robustness of the model. CONCLUSIONS: Pregabalin is shown to be a cost-saving alternative compared with duloxetine for the treatment of neuropathic pain; pregabalin would have a higher rate of patients with reduction pain (51%) than duloxetine (41%), a larger number of QALYs and would have savings (USD567.1 per patient) due to lower costs of treatment and fewer payments for medical disabilities.
PSY46
COST-UTILITY ANALYSIS OF SPINAL CORD STIMULATION IN PATIENT WITH FAILED BACK SURGERY SYNDROME: RESULTS FROM THE PRECISE STUDY
